CClinicalTrials.gg
Status unknownNCT04185129Updated Dec 4, 2019

Comparison Efficacy in Patients With Asthma Using Foster MDI and Relvar Medications

A Phase 4 interventional study of Foster in Asthma, sponsored by Far Eastern Memorial Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-12-04.

Sponsored by Far Eastern Memorial Hospital · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Enrolling by invitation — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

This is a randomized study to compare asthma patients using Foster or Relvar.

Read the detailed description

The Global Asthma Association (GAA) and the World Allergy Organization (WAO) recently issued statements stating that the small airway is caused by asthma and chronic obstructive pulmonary disease (COPD). Both pathogenesis and treatment play an important role. The small airway is an airway with diameter less than 2 mm and is one of the main sites where airflow obstruction occurs. Small particles (\<2 μm) and large particles are more likely to deposit in the distal airways, and have shown to have better effects on asthma and pulmonary obstruction. At the same time, real-life research has also shown that extra-fine particles provide better asthma control than large particles, and can better improve quality of life.The aim of the study is to compare the efficacy of asthma inhalers between extra-fine particles and non-extra-fine particles.

02

Conditions studied

  • Asthma

Browse trials for

03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 506 are open to participants now.

This study's planned enrollment of 200 is above the median of 83 across 2,751 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Far Eastern Memorial Hospital is the lead sponsor of 253 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • patients diagnosis with asthma with treatment naive
  • asthma patients with poor controlled status

Exclusion criteria

Exclusion Criteria:

  • COPD
  • smoking history
  • pregnancy
  • cardiaovascular disease
  • patients with acute respiratory infection
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Foster

    uncontrolled asthma patients were randomized into Foster treatment group

    Drug: Foster

  • Active comparator
    Relvar

    uncontrolled asthma patients were randomized into Relvar treatment group

    Drug: Foster

Interventions

  • DrugFoster

    a randomized study for comparison asthma patients using Foster or Relvar. The primary end point is lung function improvement evaluation

    Also known as: Relvar

06

What researchers measure

Primary outcomes

  1. Lung function improvement

    FEV1

    Time frame: one year

07

Study locations

1 site
  • Far Eastern Memorial Hospital
    Taipei, 886, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04185129
Lead sponsor
Far Eastern Memorial Hospital
Collaborators
Orient Europharma Co., Ltd.
Responsible party
Shih-Lung Cheng (MD. PhD, Far Eastern Memorial Hospital) — Principal investigator
First posted
Dec 4, 2019
Start date
Jan 1, 2020 (estimated)
Primary completion
Dec 31, 2021 (estimated)
Completion
Jun 30, 2022 (estimated)
Last update
Dec 4, 2019

Study contacts

Shih-Lung Cheng
principal investigator · Far Eastern Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion